Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL - Martin, M; Zielinski, C; Ruiz-Borrego, M (Ann Oncol, 2021)